These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 29159903

  • 1. Soluble major histocompatibility complex molecules in immune regulation: highlighting class II antigens.
    Bakela K, Athanassakis I.
    Immunology; 2018 Mar; 153(3):315-324. PubMed ID: 29159903
    [Abstract] [Full Text] [Related]

  • 2. Antigen processing and intracellular traffic of antigens and MHC molecules.
    Harding CV, Geuze HJ.
    Curr Opin Cell Biol; 1993 Aug; 5(4):596-605. PubMed ID: 8257600
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and tolerogenicity of self-major histocompatibility complex peptides.
    Benichou G, Takizawa PA, Ho PT, Killion CC, Olson CA, McMillan M, Sercarz EE.
    J Exp Med; 1990 Nov 01; 172(5):1341-6. PubMed ID: 1700053
    [Abstract] [Full Text] [Related]

  • 4. Peptide-MHC complexes assembled following multiple pathways: an opportunity for the design of vaccines and therapeutic molecules.
    Corradin G, Demotz S.
    Hum Immunol; 1997 May 01; 54(2):137-47. PubMed ID: 9297532
    [Abstract] [Full Text] [Related]

  • 5. Invariant chain p41 mediates production of soluble MHC class II molecules.
    Shishido T, Kohyama M, Nakai W, Matsumoto M, Miyata H, Suenaga T, Arase H.
    Biochem Biophys Res Commun; 2019 Jan 29; 509(1):216-221. PubMed ID: 30587340
    [Abstract] [Full Text] [Related]

  • 6. Presentation of antigenic peptides by products of the major histocompatibility complex.
    Fairchild PJ.
    J Pept Sci; 1998 May 29; 4(3):182-94. PubMed ID: 9643627
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Functional consequences of the binding of MHC class II-derived peptides to MHC class II.
    Feili-Hariri M, Kao H, Mietzner TA, Morel PA.
    Int Immunol; 1996 Dec 29; 8(12):1857-65. PubMed ID: 8982770
    [Abstract] [Full Text] [Related]

  • 14. Ocular production of interferon-gamma and lack of major histocompatibility complex molecules induce immunological changes in the intraocular environment.
    Geiger KD, Sarvetnick NE.
    Ger J Ophthalmol; 1996 Nov 29; 5(6):309-14. PubMed ID: 9479510
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Presentation of phagocytosed antigens by MHC class I and II.
    Mantegazza AR, Magalhaes JG, Amigorena S, Marks MS.
    Traffic; 2013 Feb 29; 14(2):135-52. PubMed ID: 23127154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.